BiotechTube
Virax Biolabs

Virax Biolabs

VRAX
London, United Kingdom· Est. 2013

Virax Biolabs is pioneering immune profiling through its ViraxImmune™ platform, which utilizes peptide pools for T cell stimulation and analysis. The company is advancing a novel portfolio of FluoroSpot T cell diagnostics towards regulatory submission, with key partnerships including Emory University for clinical studies and an upcoming FDA pre-submission meeting. Their mission is to translate immunological insights into actionable diagnostics for complex, post-viral conditions, aiming to improve global health outcomes.

viraxbiolabs.com

VRAX · Stock Price

USD 0.181.09 (-85.98%)
Market Cap: $1.4M

Historical price data

AI Company Overview

Virax Biolabs is pioneering immune profiling through its ViraxImmune™ platform, which utilizes peptide pools for T cell stimulation and analysis. The company is advancing a novel portfolio of FluoroSpot T cell diagnostics towards regulatory submission, with key partnerships including Emory University for clinical studies and an upcoming FDA pre-submission meeting. Their mission is to translate immunological insights into actionable diagnostics for complex, post-viral conditions, aiming to improve global health outcomes.

ImmunologyInfectious DiseaseNeurology

Technology Platform

The ViraxImmune™ platform utilizes proprietary pathogen-specific peptide pools to stimulate T cells, enabling detailed immune profiling and the development of FluoroSpot-based diagnostic assays for conditions involving chronic inflammation and immune dysfunction.

Funding History

2
Total raised:$14.5M
IPO$12MFeb 8, 2022
Seed$2.5MMar 15, 2021

Opportunities

The primary growth opportunity lies in addressing the massive diagnostic gap for ME/CFS and PAIS, including long COVID, where millions lack objective tests.
The platform technology allows for expansion into other T-cell-mediated chronic conditions.
Partnerships with academic centers and potential pharma collaborations for vaccine testing provide additional revenue and validation pathways.

Risk Factors

Key risks include failure to achieve regulatory approval for its lead diagnostic assays, inability to raise sufficient capital as a micro-cap stock, and challenges in commercializing a test for complex, historically subjective conditions requiring market education.
Scientific validation in ongoing clinical studies remains a critical hurdle.

Competitive Landscape

Virax Biolabs competes with large reagent suppliers (Mabtech, BD) in research tools and with diagnostic companies like Adaptive Biotechnologies in immune-based testing. Its differentiation is its specific focus on peptide-pool based T cell analysis for post-viral and chronic fatigue syndromes, a niche not deeply served by current market leaders.